Phenotypic outcomes of PKD1 compared with non-PKD1 genetically confirmed autosomal dominant polycystic kidney disease

Elhussein A. Elhassan(Royal College of Surgeons in Ireland), D. O’Donoghue(Beaumont Hospital), Sophia Heneghan(Royal College of Surgeons in Ireland), Omri Teltsh(Royal College of Surgeons in Ireland), Sahin Sarihan(Royal College of Surgeons in Ireland), Shohdan M Osman(Royal College of Surgeons in Ireland), Michelle Clince(Beaumont Hospital), David Synnott(Beaumont Hospital), Sophie Craig(Beaumont Hospital), Amy Hudson(Beaumont Hospital), Brendan Doyle(Royal College of Surgeons in Ireland), David Lappin(University Hospital Galway), Donal J. Sexton(Trinity College Dublin), Liam Casserly(University Hospital Limerick), John Holian(St. Vincent's University Hospital), Colm Magee(Beaumont Hospital), Mark Denton(Beaumont Hospital), Clodagh Sweeney(Children's Health Ireland at Crumlin), Atif Awan(Royal College of Surgeons in Ireland), Emma McCann(Children's Health Ireland at Crumlin), Gianpiero L. Cavalleri(Royal College of Surgeons in Ireland), Katherine A. Benson(Royal College of Surgeons in Ireland), Peter J. Conlon(Royal College of Surgeons in Ireland)
Journal of Nephrology
January 29, 2025
Cited by 1Open Access

Abstract

Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the most common monogenic cause of kidney failure. While identifying genetic variants predicts disease progression, characterization of recently described ADPKD-like variants is limited. We explored disease progression and genetic spectrum of genetically-confirmed ADPKD families with PKD1 and non-PKD1 variants. In this observational study, we evaluated the clinical (ADPKD-related complications, estimated glomerular filtration rate (eGFR) decline, and progression to kidney failure), radiological (height-adjusted total kidney volume (ht-TKV)), and genetic characteristics of ADPKD families referred to the Irish Kidney Gene Project. Logistic regression and Kaplan–Meier analyses examined relationships between genetic variants and disease progression. Genomic sequencing was performed on 261 ADPKD families, and 75.8% (198/261 families, comprising 391 individuals) were identified to harbor pathogenic/likely pathogenic variants; 74.2% (147/198) PKD1 families and 23.2% (46/198) non-PKD1 families, which include PKD2 (n = 29 families), IFT140 variants (n = 4), ALG5, DNAJB11 and NEK8 (n = 3 each), ALG8 and ALG9 variants (n = 2 each). The remaining 2.6% (5/198) accounted for non-ADPKD variants. Compared to PKD1, non-PKD1 families were characterized by a milder phenotype; milder eGFR decline (− 1.4 mL/min/1.73m2/year vs. − 3.2; p < 0.001), smaller ht-TKV (449.7 mL/m vs. 1769; p 0.002) and a delayed progression towards kidney failure (73 vs. 52 years; HR: 0.12, p < 0.001 [95% CI: 0.07–0.19]). ADPKD-NEK8 heterozygotes demonstrated earlier progression to kidney failure (average age 8 vs. 49 years for PKD1; Bonferroni-corrected p 0.017). Non-PKD1 variants have heterogeneous phenotypic and genotypic attributes resulting in milder disease, although ADPKD-NEK8 is an important exception with early progression.


Related Papers

No related papers found

Powered by citation graph analysis